Erythropoietin and erythropoietin receptor in colorectal cancer

International Journal of Surgical Pathology

Volumn 16, Issue 3, 2008, Pages 269-276

  Chabowska, Anna M ^a   Sulkowska, Mariola ^a   Chabowski, Adrian ^a   Wincewicz, Andrzej ^a   Koda, Mariusz ^a   Sulkowski, Stanislaw ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Colorectal cancer; Epo; EPoR; Tumor differentiation

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; RECOMBINANT ERYTHROPOIETIN;

ADENOCARCINOMA; ANEMIA; ARTICLE; CANCER SURVIVAL; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MUCINOUS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR DIFFERENTIATION;

ADENOCARCINOMA, MUCINOUS; CELL COUNT; COLORECTAL NEOPLASMS; ERYTHROPOIETIN; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; HUMANS; MALE; MIDDLE AGED; RECEPTORS, ERYTHROPOIETIN; TUMOR MARKERS, BIOLOGICAL;

EID: 45749152200     PISSN: 10668969     EISSN: None     Source Type: Journal    
DOI: 10.1177/1066896908315796     Document Type: Article

References (35)

1. Lacombe C., Mayeux P. Biology of erythropoietin. Haematologica. 1998 ; 83: 724-732.
2. Lappin T. The cellular biology of erythropoietin receptors. Oncologist. 2003 ; 8: 15-18.
3. Silva M., Grillot D., Benito A., Richard C., Nunez G., Fernandez-Luna JL Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood. 1996 ; 88: 1576-1582.
4. Stapley S., Peters TJ, Sharp D., Hamilton W. The mortality of colorectal cancer in relation to the initial symptom at presentation to primary care and to the duration of symptoms: a cohort study using medical records. Br J Cancer. 2006 ; 95: 1321-1325.
5. Farrell F., Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist. 2004 ; 9: 18-30.
6. Acs G., Acs P., Beckwith SM, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res. 2001 ; 61: 3561-3565.
7. Hardee ME, Cao Y., Fu P., et al. Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS ONE. 2007 ; 2: e549.
8. Acs G., Xu X., Chu C., Acs P., Verma A. Prognostic significance of erythropoietin expression in human endometrial carcinoma. Cancer. 2004 ; 100: 2376-2386.
9. Arany Z., Huang LE, Eckner R., et al. An essential role for p300/CBP in the cellular response to hypoxia. Proc Natl Acad Sci USA. 1996 ; 93: 12969-12973.
10. Ribatti D., Presta M., Vacca A., et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood. 1999 ; 93: 2627-2636.
11. Yasuda Y., Fujita Y., Masuda S., et al. Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs. Carcinogenesis. 2002 ; 23: 1797-1805.
12. Yasuda Y., Fujita Y., Matsuo T., et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis. 2003 ; 24: 1021-1029.
13. Hardee ME, Kirkpatrick JP, Shan S., et al. Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis. Br J Cancer. 2005 ; 93: 1350-1355.
14. Arcasoy MO, Amin K., Karayal AF, et al. Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest. 2002 ; 82: 911-918.
15. Wincewicz A., Sulkowska M., Koda M., Lesniewicz T., Kanczuga-Koda L., Sulkowski S. STAT3, HIF-1α, EPO and EPOR-signaling proteins in human primary ductal breast cancers. Folia Histochem Cytobiol. 2007 ; 45: 81-86.
16. Kanczuga-Koda L., Sulkowski S., Lenczewski A., et al. Increased expression of connexins 26 and 43 in lymph node metastases of breast cancer. J Clin Pathol. 2006 ; 59: 429-433.
17. Ribatti D., Marzullo A., Nico B., Crivellato E., Ria R., Vacca A. Erythropoietin as an angiogenic factor in gastric carcinoma. Histopathology. 2003 ; 42: 246-250.
18. Elliott S., Busse L., Bass MB, et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood. 2006 ; 107: 1892-1895.
19. Verdier F., Gomez S., Lacombe C., Mayeux P. Selected anti-Epo receptor antibodies predict Epo receptor expression [author reply]. Blood. 2006 ; 108: 1106.
20. Brown WM, Maxwell P., Graham AN, et al. Erythropoietin receptor expression in non-small cell lung carcinoma: a question of antibody specificity. Stem Cells. 2007 ; 25: 718-722.
21. Ribatti D., Marzullo A., Gentile A., et al. Erythropoietin/ erythropoietin-receptor system is involved in angiogenesis in human hepatocellular carcinoma. Histopathology. 2007 ; 50: 591-596.
22. Ribatti D., Poliani PL, Longo V., Mangieri D., Nico B., Vacca A. Erythropoietin/erythropoietin receptor system is involved in angiogenesis in human neuroblastoma. Histopathology. 2007 ; 50: 636-641.
23. Kanczuga-Koda L., Sulkowski S., Koda M., Sulkowska M. Alterations in connexin 26 expression during colorectal carcinogenesis. Oncology. 2005 ; 68: 217-222.
24. Acs G., Zhang PJ, Rebbeck TR, Acs P., Verma A. Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer. 2002 ; 95: 969-981.
25. Wen D., Boissel JP, Tracy TE, et al. Erythropoietin structure-function relationships: high degree of sequence homology among mammals. Blood. 1993 ; 82: 1507-1516.
26. Hoogsteen IJ, Peeters WJ, Marres HA, et al. Erythropoietin receptor is not a surrogate marker for tumor hypoxia and does not correlate with survival in head and neck squamous cell carcinomas. Radiother Oncol. 2005 ; 76: 213-218.
27. Lai SY, Childs EE, Xi S., et al. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene. 2005 ; 24: 4442-4449.
28. Leo C., Horn LC, Rauscher C., et al. Expression of erythropoietin and erythropoietin receptor in cervical cancer and relationship to survival, hypoxia, and apoptosis. Clin Cancer Res. 2006 ; 12: 6894-6900.
29. Westphal G., Niederberger E., Blum C., et al. Erythropoietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality. Tumori. 2002 ; 88: 150-159.
30. Rosti V., Pedrazzoli P., Ponchio L., et al. Effect of recombinant human erythropoietin on hematopoietic and non-hematopoietic malignant cell growth in vitro. Haematologica. 1993 ; 78: 208-212.
31. Westenfelder C., Baranowski RL Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int. 2000 ; 58: 647-657.
32. Acs G., Chen M., Xu X., Acs P., Verma A., Koch CJ Autocrine erythropoietin signaling inhibits hypoxia-induced apoptosis in human breast carcinoma cells. Cancer Lett. 2004 ; 214: 243-251.
33. Mohyeldin A., Lu H., Dalgard C., et al. Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma. Neoplasia. 2005 ; 7: 537-543.
34. Acs G., Zhang PJ, McGrath CM, et al. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol. 2003 ; 162: 1789-1806.
35. Sulkowska M., Wincewicz A., Chabowska A., et al. To give or not to give recombinant Epo to anemia endangered cancer patients. Prague Med Rep. 2006 ; 107: 281-290.